Share this video  

ITOC 2021 | Pionyr Immunotherapeutics: overview and the potential of PY159 for the treatment of solid tumors

Alicia Levey, BA, PhD, Pionyr Immunotherapeutics, San Francisco, CA, gives an overview of Pionyr Immunotherapeutics and its ongoing work in developing antibody-based therapeutics for modulating myeloid cells present in the tumor microenvironment to enhance anti-tumor immunity. Following on, Vladi Juric, PhD, Pionyr Immunotherapeutics, San Francisco, CA, gives an overview of the pre-clinical assessment of PY159, an anti-TREM1 monoclonal antibody, for the treatment of solid tumors. TREM1 is a pro-inflammatory cell surface receptor expressed on normal and tumor-associated myeloid cells, where it plays a role in immunosuppression. PY159 is currently being evaluated in a Phase Ia clinical trial in patients resistant and refractory to standard of care therapies (NCT04682431). This interview took place at the virtual 8th Immunotherapy of Cancer Conference (ITOC) 2021.